It is estimated that about 7-10 percent of U.S. physicians currently dispense pharmaceuticals to their patients. These doctors come from every clinical perspective: student health centers, urgent care clinics, occupational medicine clinics, surgery centers, family practice, weight management practices, worksite clinics, pediatrics, podiatry, dermatology etc. Physicians see dispensing as a mechanism for providing convenience to the patient while supplementing practice revenue.  Physician dispensing is a proven way to generate revenue in a world of shrinking reimbursements.  Many clinics charge nominal fees for dispensed medications and offer a variety of prepackaged pharmaceuticals in counts ranging from 6-50 pills per bottle.  Medication dispensing, a tool for all types of physicians to better serve their patients while growing their practices.

Schedule a free claims analysis now.

Let’s Talk now

Leader in AI-driven health benefits navigation Healthee partners with Northwind

Katherine Lurk | Mar 28th, 2025
A game-changer for employers looking to cut costs and gain control With healthcare costs continuing to rise, employers are seeking new ways to rein in spending without sacrificing the quality of benefits. This partnership enables Healthee clients to optimize prescription drug management, reducing costs through preferable generic drug pricing, high-touch chronic care programs, and more. … more »

continue reading

Healthcare Storm 2025: What Will It Be?

Phillip Berry | Jan 1st, 2025
When it comes to American healthcare, we’ve become really good at highlighting its failings. Watching the flurry of lamentations, frustrations, denigrations, and prognostications, over the last few weeks, would lead any rational person to believe that nothing is working in our healthcare system. And, not only is it “not working,” many people conclude that it … more »

continue reading

New Drugs to Market – October Update

Phillip Berry | Oct 25th, 2024
The Food and Drug Administration (FDA) approved three novel drug therapies in October. One of those therapies,  Hympavzi (marstacimab-hncq), is a medication indicated for the treatment of patients with Hemophilia A and Hemophilia B. Hympavzi utilizes a new pathway to help reduce the risk of bleeding episodes in patients with Hemophilia, a disease that impacts … more »

continue reading